GlassScriptPhysician profile
Sara B Bush
NPI 1215165311
$4,517.40
in general payments reported to CMS, 2019-2025
30 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $655 · 2021: $646 · 2022: $566 · 2023: $831 · 2024: $364 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.54 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $635.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $459.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.13 | 2020-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $367.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $361.53 | 2020-2025 | |
| Astellas Pharma US INC | $315.19 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.97 | 2019-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $195.06 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Vanda Pharmaceuticals INC. | $192.49 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $183.71 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $178.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $135.43 | 2019-2023 | Verquvo, Belsomra, Lagevrio |
| Janssen Pharmaceuticals, INC | $127.97 | 2019-2022 | |
| Amgen INC. | $102.94 | 2019-2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $87.09 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $79.57 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $58.69 | 2020-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.01 | 2025 | Caplyta |
| Cranial Technologies, INC | $44.30 | 2019-2024 | Doc Band |
| Phathom Pharmaceuticals, INC. | $35.47 | 2025 | Voquezna |
| Dexcom, INC. | $34.14 | 2021-2023 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $30.45 | 2021 | |
| Eisai INC. | $25.46 | 2020-2022 | |
| Glaxosmithkline, LLC. | $24.10 | 2022 | |
| Smith+Nephew, INC. | $23.33 | 2022 | |
| Mylan Specialty L.P. | $22.21 | 2022 | |
| Sumitomo Pharma America, INC. | $20.44 | 2025 | Myfembree |
| Biohaven Pharmaceuticals, INC. | $20.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.36 | 2019 | |
| Duchesnay USA Incorporated | $16.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.